1.
J Investig Allergol Clin Immunol
; 18(5): 335-42, 2008.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18973096
RESUMO
Recombinant protein technology and the subsequent development of biologic agents for pharmacotherapy have greatly improved the treatment of a wide variety of diseases in humans. These products are subject to reactions not previously seen in other drug classes. Additionally, subtle alteration in the manufacture or administration of a biologic agent may cause reactions in subjects who previously tolerated it. This review highlights the unique immunologic reactions that are associated with the more commonly used biologic agents.